STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Personalized vaccine takes on head and neck cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see i…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
Cholesterol drug boosts immunotherapy in head and neck cancer trial
Disease control Recruiting nowThis study tests whether adding a common cholesterol-lowering drug (lovastatin) to an immunotherapy (pembrolizumab) can shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has a specific marker (PD-L1 CPS ≥ 1) will receive b…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
New combo aims to shrink tumors and cut radiation for young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New combo aims to keep nasopharyngeal cancer at bay longer
Disease control Recruiting nowThis study tests whether adding a second immunotherapy drug (relatlimab) to the standard immunotherapy (nivolumab) can help keep nasopharyngeal cancer from growing or spreading for a longer time. About 156 people with recurrent or metastatic Epstein-Barr virus-associated nasophar…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
Can blood tests predict who will do their swallowing exercises?
Knowledge-focused Recruiting nowThis study looks at why people with head and neck cancer follow (or don't follow) swallowing exercises after radiation. Researchers will use blood tests and questionnaires to see if immune system proteins or feelings about the disease affect exercise habits. The goal is to find w…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:08 UTC
-
Remote hearing tests could save cancer Patients' hearing
Knowledge-focused Recruiting nowThis study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:57 UTC